TheEbenezer News

Breaking

Sun Pharma agrees to supply atMFN pricing to U.S. medicaid programmes

The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.

This story summarizes reporting from The Hindu. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.

Read full story on The Hindu
The Hindu1 Sept 2026, 04:33 pmUpdated 1h ago1 min readBusinessIndia
Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes

IndiaThe Hindu

The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.

This report is published with credit to The Hindu. The wire sent a summary; open the original for any extra context. Read on The Hindu

Source: The Hindu. Published 1 Sept 2026, 04:33 pm.

Keep reading

Back to the desk
info@ebenezerdigital.com+91 98944 96560WhatsApp